ASCO 2023 | Future direction of 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma

Sujay A. Vora, MD, Mayo Clinic, Phoenix, AZ, discusses the results of a Phase II (NCT03778294) trial investigating short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma, which demonstrated improved overall-survival (OS) and progression-free survival (PFS) for all patients. Further improvement was shown in patients with MGMT methylation. Future directions within this line of research include an upcoming trial with a larger group of patients randomizing patients to short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI versus the standard of care radiation over 3-6 weeks with standard radiation photon-based treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.